Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition

J Exp Med. 1992 Jul 1;176(1):119-28. doi: 10.1084/jem.176.1.119.

Abstract

The routes used by antigen-presenting cells (APC) to convert the transmembrane fusion glycoprotein (F) of measles virus (MV) to HLA class I and class II presentable peptides have been examined, using cloned cytotoxic T lymphocytes in functional assays. Presentation by Epstein-Barr virus-transformed B lymphoblastoid cell lines was achieved using live virus, ultraviolet light-inactivated virus, and purified MV-F delivered either as such or incorporated in immunostimulating complexes (MV-F-ISCOM). Only live virus and MV-F-ISCOM allow presentation by class I molecules, while all antigen preparations permit class II-restricted presentation. We observe presentation of MV-F from live virus and as MV-F-ISCOM by class II molecules in a fashion that is not perturbed by chloroquine. Our studies visualize novel presentation pathways of type I transmembrane proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigen-Presenting Cells / physiology
  • CD4 Antigens / analysis
  • CD8 Antigens / analysis
  • Histocompatibility Antigens Class I / immunology*
  • Histocompatibility Antigens Class II / immunology*
  • Humans
  • Lymphocyte Activation*
  • Measles virus / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Viral Fusion Proteins / biosynthesis*
  • Viral Fusion Proteins / immunology

Substances

  • CD4 Antigens
  • CD8 Antigens
  • Histocompatibility Antigens Class I
  • Histocompatibility Antigens Class II
  • Viral Fusion Proteins